LYEL
Lyell Immunopharma Inc
9.10$
-2.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -150,744.0% | -312,576.9% | -1,400,533.3% | -293,030.8% | -103,064.7% | -429,472.7% | -781,971.4% | -430,725.0% | -190,513.3% | -537,516.7% | -1,925,500.0% | -848,050.0% | -493,555.6% | |
| 20,416.0% | 38,900.0% | 167,466.7% | 37,700.0% | 13,764.7% | 45,690.9% | 49,157.1% | 39,187.5% | 17,106.7% | 39,950.0% | 116,600.0% | 55,550.0% | 35,248.1% | |
| 42,064.0% | 65,100.0% | 305,166.7% | 63,723.1% | 22,417.6% | 73,481.8% | 86,057.1% | 62,550.0% | 34,880.0% | 426,150.0% | 214,750.0% | 113,300.0% | 146,770.4% | |
| 9,704.0% | 13,246.2% | -107,900.0% | -7,338.5% | 3,050.0% | 309.1% | -136,485.7% | -10,950.0% | -906.7% | 11,200.0% | -54,200.0% | 196,325.0% | 27,055.6% | |
| 780.0% | 192.3% | 1,000.0% | 2,546.2% | 173.5% | 400.0% | 3,514.3% | 2,100.0% | 413.3% | 5,066.7% | 4,450.0% | 6,400.0% | 2,633.3% | |
| 398,688.0% | -774,538.5% | 733,133.3% | 346,207.7% | 5,641.2% | 486,409.1% | 992,371.4% | 158,087.5% | 22,326.7% | -522,750.0% | 868,900.0% | 390,400.0% | 18,437.0% | |
| -860.0% | -946.2% | -2,533.3% | 6,230.8% | -2,158.8% | 327,372.7% | – | – | – | – | – | – | – | |
| -572.0% | 5,838.5% | 900.0% | 6,630.8% | 0.0% | 3,972.7% | 14.3% | 2,287.5% | 333,333.3% | 3,700.0% | 2,586,100.0% | 13,050.0% | 379,503.7% | |
| 247,368.0% | -1,081,284.6% | -666,566.7% | 59,800.0% | -97,423.5% | 48,163.6% | 210,414.3% | -270,350.0% | 165,140.0% | -1,056,566.7% | 1,529,450.0% | -444,600.0% | -95,622.2% | |
| -151,524.0% | -312,769.2% | -1,401,533.3% | -295,576.9% | -103,238.2% | -429,872.7% | -785,485.7% | -432,825.0% | -190,926.7% | -542,583.3% | -1,929,950.0% | -854,450.0% | -496,188.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.